Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors

Published:2018-05 Issue: Volume:272 Page:33-40
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Lim Soo^ORCID,Eckel Robert H.,Koh Kwang Kon

Funder

Korea Health Industry Development Institute (KHIDI)

Ministry for Health and Welfare, Korea

Korean Society of CardioMetabolic Syndrome

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference77 articles.

1. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes;Nissen;N. Engl. J. Med.,2007

2. Glucose control and vascular complications in veterans with type 2 diabetes;Duckworth;N. Engl. J. Med.,2009

3. Long-term effects of intensive glucose lowering on cardiovascular outcomes;Gerstein;N. Engl. J. Med.,2011

4. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes;Patel;N. Engl. J. Med.,2008

5. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes;Green;N. Engl. J. Med.,2015

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes;BMC Medicine;2024-07-02

2. Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes;Journal of Diabetes Investigation;2024-04-27

3. A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin;Diabetes, Obesity and Metabolism;2024-02-29

4. Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: Location‐F study;Diabetes, Obesity and Metabolism;2023-12-11

5. Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study;Diabetes Research and Clinical Practice;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3